The Drive to Discover. The Experience to Deliver.
|View printer-friendly version|
|Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis|
About the Phase III Program
Four Phase III RA studies are planned, which will investigate the safety and efficacy of baricitinib 2 mg and 4 mg once daily in patients with active RA who are methotrexate-naive, biologic-naive or biologic-experienced. Patients completing any of the four studies will be eligible for enrollment in a fifth study, a long-term extension. Information about the clinical trials can be viewed at www.clinicaltrials.gov.
Except for the historical information set forth herein, the matters set
forth in this press release, including the statement with respect to the
Phase III program being expected to include four Phase III studies,
contain predictions, estimates and other forward-looking statements.
These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including the high
degree of risk and uncertainty associated with drug development and
clinical trials, the ability to enroll a sufficient number of patients,
and other risks detailed from time to time in
Links to third-party websites or pages are provided for convenience
you to consult these policy statements.
The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.
- Stock Information
- Earnings Estimates
- Quarterly Results
- Press Releases
- Analysts Coverage
- Events & Webcasts
- Annual Reports
- Proxy Information
- SEC Filings
- Corporate Governance
- Investor FAQ
- Information Request
- Contact Us